RefluxStop™ Proves Cost-Effective for Treating GERD in Swiss Study

RefluxStop™ Outperforms Traditional GERD Treatments

Recent research has shown that RefluxStop™ is more cost-effective compared to other treatments for gastroesophageal reflux disease (GERD) in Switzerland. This data was highlighted in a study published in the Journal of Medical Economics.

The study revealed that patients using RefluxStop™ experienced not only greater improvements in quality of life but also incurred lower healthcare costs. These findings are significant when compared against other established treatments like Nissen fundoplication, the LINX system, and medication-based approaches.

Study Details and Collaborations

The comprehensive health economic analysis involved collaboration between the York Health Economics Consortium in the UK and top reflux centers in Switzerland. Notable contributors included Dr. med. Yves Borbély from Inselspital Bern University Hospital and Prof. Dr. med. Joerg Zehetner from Swiss1Chirurgie, Hirslanden Klinik Beau-Site.

The research provided a convincing argument for the adoption of RefluxStop™ within the Swiss healthcare system. This was primarily due to higher Quality Adjusted Life Year (QALY) scores and overall cost savings when compared to traditional treatments.

Implantica's Vision for GERD Treatment

Implantica's CEO, Dr. Peter Forsell, expressed gratitude towards the independent surgeons who evaluated the economic impact of RefluxStop™. He emphasized the potential of this innovative device to alleviate the financial burden of GERD in Switzerland, where over 993,000 individuals are affected annually, costing around CHF 230 million.

RefluxStop™ stands out by addressing the root causes of acid reflux without applying pressure on the food passageway, unlike conventional surgical methods. This novel approach helps restore the natural functioning of the lower esophageal sphincter, providing a more effective and less invasive solution.

Looking Ahead: The Role of RefluxStop™

By maintaining the lower esophageal sphincter's correct anatomical position, RefluxStop™ helps the body to combat acid reflux naturally. This offers a promising alternative to patients who have had limited success with other treatments.

The device's unique mechanism not only enhances patients' quality of life but also presents a viable option for reducing healthcare expenditures, making it a valuable addition to the treatment landscape for GERD.

References and Further Reading

For more information, please visit Implantica's official website or consult the Journal of Medical Economics for the full study. Implantica continues to explore innovative solutions and remains committed to improving patient outcomes through technology.

Further contact details include reaching out to Implantica's Chief Corporate Affairs Officer, Nicole Pehrsson, or visiting their Nasdaq listing for more updates on the company's developments.